Multi-Infarct Dementia Market By Causes 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Multi-Infarct Dementia Market
Multi-Infarct Dementia Market: By Causes (Anemia, Brain Tumor, Chronic Infection, Depression, Thyroid Disease, Othes), By Pharmacological Treatment (Cheis, Donepezil, Galantamine, Rivastigmine, Others) & By Region-Forecast (2016-2021)
Report Code : HCR 0295
Updated Date: 17 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Multi-infarct dementia (MID) is one of the common causes of memory loss among elderly people as a result of reduced blood flow to parts of the brain. The primary reason for multi-infarct dementia is a series of minor strokes resulting in disruption of blood flow leading towards the brain. Globally, Development of efficient and advance technology, Rise in the demand for noval diagnostic Product. Rising demand for point of care devices segment and Growing demand for Multi-Infarct Dementias demand in end-use industries are the prime growth drivers of global Near Infrared Imaging market. In addition, increase in adoption of Multi-Infarct Dementia for newer applications, will create new opportunities for global Near multi infarct dementia market. However, higher cost of the research and development, lack of awareness and Sustainability in market are the key restraints for global Near Infrared Imaging market.

This report identifies the global Multi-Infarct Dementia market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Multi-Infarct Dementia market.
Multi-Infarct Dementia Market

Geographically North America dominated global Multi-Infarct Dementia market, and Europe is projected to have fastest growth, while it is the most common type of dementia in Asia and other parts of the world. For instance, it accounts for more than 50% of dementia cases in Japan. The prevalence of multi-infarct dementia (MID) is expected to rise drastically in the near future given the exponential rise in geriatric population of the world. Therefore, the global multi-infarct dementia (MID) market is expected to grow rapidly in the developed nations such as the U.S., Canada, Germany, France, and Japan where there is enormous rise in the elderly people.

This report segments global Multi-Infarct Dementia market on the basis of product type, application, end-user, and regional market as follows:
  • Multi-Infarct Dementia Market, By Causes (Anemia, Brain Tumor, Chronic Infection, Depression, Thyroid Disease, Vitamin Deficiency, Drug Intoxication and Others
  • Multi-Infarct Dementia Market, By Pharmacological Treatment (Cheis, Donepezil, Galantamine, Rivastigmine, Memantine, Nimodipine,Hydergine, CDP-Choline) and Others
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the Multi-Infarct Dementia market. Some of the major companies’ profiles in detail are as follows:
  • Accelerys Inc.
  • Affymetrix
  • Agilent technologies
  • Celera Corporation
  • DNAnexus
1. Multi-Infarct Dementia Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Multi-Infarct Dementia Market– Market Forces
   4.1. Drivers
      4.1.1. Development of efficient and advance technology
      4.1.2. Rise in the demand for noval diagnostic Product.
   4.2. Restraints
      4.2.1. Higher cost of research and development
      4.2.2. Sustainability in market.
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of Multi-Infarct Dementia for newer applications
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Multi-Infarct Dementia Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Multi-Infarct Dementia Market, By Causes Type
   6.1. Anemia
   6.2. Brain Tumor
   6.3. Chronic Infection
   6.4. Depression
   6.5. Thyroid Disease
   6.6. Vitamin Deficiency
   6.7. Drug Intoxication
   6.8. Others
7. Multi-Infarct Dementia Market, By Pharmacological Treatment
   7.1. Cheis
   7.2. Donepezil
   7.3. Galantamine
   7.4. Rivastigmine
   7.5. Memantine
   7.6. Nimodipine
   7.7. Hydergine
   7.8. CDP-Choline
   7.9. Others
8. Multi-Infarct Dementia Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Multi-Infarct Dementia – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Abbott Laboratories
   10.2. Alere Inc
   10.3. Bayer Healthcare
   10.4. Becton Dickinson
   10.5. bioMerieux
   10.6. Bio-Rad Laboratories
   10.7. Cepheid
   10.8. Dako
   10.9. Danaher Corporation
   10.10. Hologic(Gen Probe)
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports